COG Stock Overview
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health solutions in the United States, United Kingdom, the European Union, and internationally.
Cambridge Cognition Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£1.33|
|52 Week High||UK£1.95|
|52 Week Low||UK£0.99|
|1 Month Change||-17.70%|
|3 Month Change||4.33%|
|1 Year Change||6.86%|
|3 Year Change||92.03%|
|5 Year Change||13.73%|
|Change since IPO||65.63%|
Recent News & Updates
|COG||GB Healthcare Services||GB Market|
Return vs Industry: COG exceeded the UK Healthcare Services industry which returned -38% over the past year.
Return vs Market: COG exceeded the UK Market which returned -3.8% over the past year.
|COG Average Weekly Movement||9.4%|
|Healthcare Services Industry Average Movement||7.5%|
|Market Average Movement||6.2%|
|10% most volatile stocks in GB Market||11.8%|
|10% least volatile stocks in GB Market||3.2%|
Stable Share Price: COG is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: COG's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health solutions in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, an online patient recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer’s disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from Phases I–IV; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps for data collection to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; and CANTAB Insight, a medical device that helps to determine an individual’s cognitive health.
Cambridge Cognition Holdings Fundamentals Summary
|COG fundamental statistics|
Is COG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|COG income statement (TTM)|
|Cost of Revenue||UK£2.02m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.014|
|Net Profit Margin||4.46%|
How did COG perform over the long term?See historical performance and comparison
Is Cambridge Cognition Holdings undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: COG (£1.33) is trading below our estimate of fair value (£6.18)
Significantly Below Fair Value: COG is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: COG is poor value based on its PE Ratio (91.4x) compared to the European Healthcare Services industry average (35x).
PE vs Market: COG is poor value based on its PE Ratio (91.4x) compared to the UK market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate COG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: COG is overvalued based on its PB Ratio (65.1x) compared to the GB Healthcare Services industry average (2.6x).
How is Cambridge Cognition Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if COG's forecast earnings growth is above the savings rate (0.9%).
Earnings vs Market: Insufficient data to determine if COG's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: COG's revenue (11% per year) is forecast to grow faster than the UK market (4.1% per year).
High Growth Revenue: COG's revenue (11% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if COG's Return on Equity is forecast to be high in 3 years time
How has Cambridge Cognition Holdings performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COG has high quality earnings.
Growing Profit Margin: COG became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: COG has become profitable over the past 5 years, growing earnings by -5.3% per year.
Accelerating Growth: COG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: COG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-3%).
Return on Equity
High ROE: Whilst COG's Return on Equity (71.2%) is outstanding, this metric is skewed due to their high level of debt.
How is Cambridge Cognition Holdings's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: COG's short term assets (£12.1M) exceed its short term liabilities (£11.9M).
Long Term Liabilities: COG has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: COG is debt free.
Reducing Debt: COG has not had any debt for past 5 years.
Debt Coverage: COG has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: COG has no debt, therefore coverage of interest payments is not a concern.
What is Cambridge Cognition Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate COG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate COG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if COG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if COG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as COG has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Matthew Stork has been the Chief Executive Officer at Cambridge Cognition Holdings Plc since May 24, 2019 and has been its Director since May 23, 2019. He was Chief Operating Officer of Cambridge Cogni...
CEO Compensation Analysis
Compensation vs Market: Matthew's total compensation ($USD475.18K) is above average for companies of similar size in the UK market ($USD311.51K).
Compensation vs Earnings: Matthew's compensation has been consistent with company performance over the past year.
Experienced Management: COG's management team is considered experienced (3 years average tenure).
Experienced Board: COG's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cambridge Cognition Holdings Plc's employee growth, exchange listings and data sources
- Name: Cambridge Cognition Holdings Plc
- Ticker: COG
- Exchange: AIM
- Founded: 2012
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: UK£41.147m
- Shares outstanding: 31.05m
- Website: https://www.cambridgecognition.com
Number of Employees
- Cambridge Cognition Holdings Plc
- Tunbridge Court
- Tunbridge Lane
- CB25 9TU
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.